Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
© Wu et al. 2016
Received: 23 February 2016
Accepted: 1 March 2016
Published: 9 March 2016
More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s macroglobulinemia. More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored. Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib. This review summarized the preclinical research and clinical data of acalabrutinib.
New CD20 monoclonal antibodies and bispecific antibodies are providing more treatment options with increasing precision and potency for hematological malignancies [1–7]. Even though chronic lymphocytic leukemia (CLL) remains incurable at this time, more and more treatment options are bringing clinical benefits to patients with longer duration of response and less toxicities commonly seen with conventional chemotherapeutic agents [1, 8–11]. Bruton’s tyrosine kinase (BTK) is an essential kinase in the B cell receptor (BCR) signaling pathway and a driving force for CLL and other B cell malignancies [12–14]. The first-in-class BTK inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and Waldenstrom’s macroglobulinemia [11, 13, 15–17]. However, ibrutinib has untoward effects, such as bleeding, rash, and atrial fibrillation, which could be partly due to the bystander effects on targets other than BTK [10, 13, 15, 17, 18]. Therefore, more selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored [19–23]. Acalabrutinib, also known as ACP-196, is a novel irreversible second-generation BTK inhibitor that was rationally designed to be more potent and selective than ibrutinib [19, 24–28]. This review summarized the preclinical research and clinical data of acalabrutinib.
Mechanism of action and properties of acalabrutinib
Acalabrutinib binds covalently to Cys481 with improved selectivity and in vivo target coverage compared to ibrutinib and CC-292 in CLL patients [19, 20, 26]. In the in vitro signaling assay on primary human CLL cells, acalabrutinib inhibited tyrosine phosphorylation of downstream targets of ERK, IKB, and AKT . Acalabrutinib demonstrated higher selectivity for BTK with IC50 determinations on nine kinases with a cysteine residue in the same position as BTK . Importantly, unlike ibrutinib, acalabrutinib did not inhibit EGFR, ITK, or TEC [19, 24]. In the in vitro assays reported in the supplemental data, it was clearly demonstrated that, unlike ibrutinib, acalabrutinib had no effect on EGFR phosphorylation on tyrosine residues y1068 and y1173. At 1000 nM, ibrutinib completely suppressed Tec activity, though 1000 nM acalabrutinib had minimal activity on Tec . Compared with ibrutinib, acalabrutinib has much higher IC50 (>1000 nM) or virtually no inhibition on kinase activities of ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, and YES1 .
The differential effects of acalabrutinib on primary CLL cells, T cells, NK cells, and epithelial cells were studied by signaling and functional assays. Acalabrutinib inhibited purified BTK with an IC50 of 3 nM and EC50 of 8 nM in a human whole-blood CD69 B cell activation assay . Acalabrutinib was shown to have improved target specificity over ibrutinib with 323-, 94-, 19-, and 9-fold selectivity over the other TEC kinase family members (ITK, TXK, BMX, and TEC, respectively) and no activity against EGFR.
The effects of ibrutinib and acalabrutinib on platelets were also compared in an in vivo VWFHA1 mouse thrombosis model. The platelets from patients treated with ibrutinib 420 mg once per day or acalabrutinib 100 mg twice per day were assessed for thrombus formation at injured arterioles of the mice. The thrombus sizes from acalabrutinib-treated platelets were comparable to those of healthy controls, whereas thrombus formation was clearly inhibited in ibrutinib-treated platelets. These data suggest that acalabrutinib, unlike ibrutinib, is more selective for inhibiting BTK and has virtually no inhibition of platelet activity .
There data clearly suggest that acalabrutinib is a more selective and potent second-generation BTK inhibitor.
Acalabrutinib (ACP-196) in preclinical research
Acalabrutinib was evaluated in several animal models of B cell non-Hodgkin lymphoma (NHL). These studies provided preclinical in vivo data necessary to move acalabrutinib into human trials. In a study of canine model of B cell NHL, 12 dogs with B cell NHL were orally administered acalabrutinib at escalating dosages of 2.5 mg/kg every 24 h (6 dogs), 5 mg/kg every 24 h (5 dogs), or 10 mg/kg every 12 h (1 dog). As a result, 3 dogs achieved a partial remission (PR), 3 dogs had stable disease (SD), whereas the remaining 6 dogs had progression of disease (PD). This study therefore showed that acalabrutinib has single agent biologic activity in a spontaneous large animal model of NHL .
The in vivo effects of acalabrutinib against CLL cells were demonstrated in the NSG mouse model with xenografts of human CLL . Acalabrutinib significantly inhibited proliferation of human CLL cells in the spleens of NSG mice at all dose levels, as measured for the expression of Ki67 (P = 0.002). Tumor burden decreased with the treatment of acalabrutinib in a dose-dependent manner. Acalabrutinib inhibited BCR signaling by reduced phosphorylation of PLCγ2. Acalabrutinib transiently increased CLL cell counts in the peripheral blood. Therefore, the novel BTK inhibitor acalabrutinib shows in vivo efficacy against human CLL cells xenografted to the NSG mouse model.
Two murine models were used in another in vivo study [29, 30]. In the TCL1 adoptive transfer model, acalabrutinib inhibited BCR signaling by decreased autophosphorylation of BTK and reduction in surface expression of the BCR activation markers CD86 and CD69. Most interestingly, acalabrutinib treatment increased survival significantly over mice receiving vehicle (median 81 vs 59 days, P = 0.02). The second murine model was the NSG xenograft model. Acalabrutinib treatment significantly decreased the phosphorylation of PLCγ2 and ERK (P = 0.02), reduced tumor cell proliferation (P = 0.02), and tumor burden (P = 0.04). Acalabrutinib was shown to be a potent inhibitor of BTK in both murine models of human CLL .
Acalabrutinib in clinical development
To further assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib in human CLL, a phase 1/2, multicenter, open-label, and dose-escalation clinical trial has been ongoing (NCT02029443). In the latest report, 61 patients with relapsed CLL were enrolled . These patients had received a median of three prior therapies for CLL. Among them, 31 % were positive for 17p13.1 deletion and 75 % had IGvH unmutated. In the phase 1 portion of this study, patients were treated with acalabrutinib at an increasing dose of 100 to 400 mg once daily. In the phase 2 expansion portion, 100 mg twice daily was given. After a median follow-up of 14.3 months (range 0.5–20), the overall response rate (ORR) was 95 %, with 85 % PR, 10 % PR with lymphocytosis. The remaining 5 % of patients were reported to have SD. The ORR was 100 % in those patients with chromosome 17p13.1 deletion. Headache, diarrhea, and weight gain were the most common adverse events. There were no dose-limiting toxicities observed in the phase I portion of the trial. There was no Richter’s transformation and no cases of atrial fibrillation have been reported to date . The preclinical data from this report confirmed that acalabrutinib is a highly selective BTK inhibitor. It does not inhibit TEC kinase and platelet aggregation which would be a preferred advantage over ibrutinib and would have reduced bleeding risk. Acalabrutinib does not inhibit EGFR, thus could reduce the adverse events on skin rash and severe diarrhea. Transient headaches were reported to be a common adverse event from acalabrutinib and appeared to be more frequently seen than in those patients on ibrutinib from historical data. More patients and longer follow-up from this study are needed to ascertain these potential advantages and disadvantages. In addition, direct comparison of acalabrutinib with ibrutinib will be the only way to confirm the advantages and disadvantages of these agents.
Acalabrutinib (ACP-196) for hematological malignancies
CLL, SLL, PLL
NHL, MM, B-All
CLL, SLL, RS, PLL
NHL, MM, HL, CLL, RS, WM, Myelofibrosis
Conclusion and future directions
Acalabrutinib (ACP-196) for solid tumors
Non-small-cell lung cancer
Head and neck
Squamous cell carcinoma
Jingjing Wu is a recipient of the Henan Provincial Grant for Overseas Research for Young Leaders of Medical Technology (No. 2014041). She also received grant support from the Natural Science Foundation of China (NSFC No. 81201793). The grants supported her research training at the Division of Hematology and Oncology, New York Medical College and Westchester Medical Center, Valhalla, NY, USA.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10.View ArticlePubMedGoogle Scholar
- Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. J Hematol Oncol. 2015;8(1):1–14.View ArticleGoogle Scholar
- Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, et al. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7(3):584–604.View ArticlePubMedGoogle Scholar
- Suresh T, Lee L, Joshi J, Barta S. New antibody approaches to lymphoma therapy. J Hematol Oncol. 2014;7(1):58.View ArticlePubMedPubMed CentralGoogle Scholar
- Thomas X. Blinatumomab: a new era of treatment for adult ALL? Lancet Oncol. 2014;16(1):6–7.View ArticlePubMedGoogle Scholar
- Wu J, Fu J, Zhang M, Liu D. AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. J Hematol Oncol. 2015;8:96.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu J, Fu J, Zhang M, Liu D. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol. 2015;8(1):104.View ArticlePubMedPubMed CentralGoogle Scholar
- Cang S, Iragavarapu C, Savooji J, Song Y, Liu D. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol. 2015;8(1):129.View ArticlePubMedPubMed CentralGoogle Scholar
- Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–22.View ArticlePubMedGoogle Scholar
- Rai K. Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. J Hematol Oncol. 2015;8(1):85.View ArticlePubMedPubMed CentralGoogle Scholar
- Novero A, Ravella PM, Chen Y, Dous G, Liu D. Ibrutinib for B cell malignancies. Experimental Hematology & Oncology. 2014;3(1):1–7.View ArticleGoogle Scholar
- Treon SP, Xu L, Hunter Z. MYD88 mutations and response to ibrutinib in Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;373(6):584–6.View ArticlePubMedGoogle Scholar
- Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;372(15):1430–40.View ArticlePubMedGoogle Scholar
- Cao Y, Yang G, Hunter ZR, Liu X, Xu L, Chen J, et al. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015;170(1):134–8.View ArticlePubMedGoogle Scholar
- Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.View ArticlePubMedPubMed CentralGoogle Scholar
- Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, et al. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015;125(19):2915–22.View ArticlePubMedPubMed CentralGoogle Scholar
- Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37.View ArticlePubMedGoogle Scholar
- Covey T, Barf T, Gulrajani M, Krantz F, van Lith B, Bibikova E, et al. Abstract 2596: ACP-196: a novel covalent Bruton’s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Cancer Res. 2015;75(15 Supplement):2596.View ArticleGoogle Scholar
- Vidal-Crespo A, Rodríguez V, Matas-Céspedes A, Campos E, López-Guillermo A, Roué G, et al. Abstract 1757: the novel BTK inhibitor CC-292 exerts in vitro and in vivo antitumor activity, interferes with adhesion, cell migration, and synergizes with lenalidomide in MCL models. Cancer Res. 2014;74(19 Supplement):1757.View ArticleGoogle Scholar
- Na L, Zhijian S, Ye L, Mingming G, Yilu Z, Dongping Z, et al. Abstract 2597: BGB-3111 is a novel and highly selective Bruton’s tyrosine kinase (BTK) inhibitor. Cancer Res. 2015;75:2597.View ArticleGoogle Scholar
- Tam C, Grigg AP, Opat S, Ku M, Gilbertson M, Anderson MA, et al. The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial. Blood. 2015;126(23):832.Google Scholar
- Walter HS, Rule SA, Dyer MJS, Karlin L, Jones C, Cazin B, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127(4):411–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–32.View ArticlePubMedGoogle Scholar
- Gardner* HL, Harrington* BK, Izumi R, Hamdy A, Kaptein A, Lith BV, et al. Abstract 1744: ACP-196: a second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma. Cancer Res. 2014;74(19 Supplement):1744.View ArticleGoogle Scholar
- Harrington BK, Gulrajani M, Covey T, Kaptein A, Van Lith B, Izumi R, et al. ACP-196 is a second generation inhibitor of Bruton tyrosine kinase (BTK) with enhanced target specificity. Blood. 2015;126(23):2908.Google Scholar
- Lannutti BJ, Gulrajani M, Krantz F, Bibikova E, Covey T, Jessen K, et al. Abstract 408: ACP-196, an orally bioavailable covalent selective inhibitor of Btk, modulates the innate tumor microenvironment, exhibits antitumor efficacy and enhances gemcitabine activity in pancreatic cancer. Cancer Res. 2015;75(15 Supplement):408.View ArticleGoogle Scholar
- Niemann CU, Montraveta A, Herman SEM, Ingallinera T, Barf T, Colomer D, et al. Abstract 2624: the novel Bruton’s tyrosine kinase inhibitor ACP-196 shows in vivo efficacy against human chronic lymphocytic leukemia cells xenografted to the NSG mouse model. Cancer Res. 2014;74(19 Supplement):2624.View ArticleGoogle Scholar
- Herman SEM, Montraveta A, Niemann CU, Mora-Jensen H, Gulrajani M, Krantz F, et al. The Bruton tyrosine kinase (BTK) inhibitor ACP-196 demonstrates clinical activity in two mouse models of chronic lymphocytic leukemia. Blood. 2015;126(23):2920.Google Scholar
- Herman SE, Sun X, McAuley EM, Hsieh MM, Pittaluga S, Raffeld M, et al. Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia. 2013;27(12):2311–21.View ArticlePubMedPubMed CentralGoogle Scholar
- Rai KR, Barrientos JC. Movement toward optimization of CLL therapy. N Engl J Med. 2014;370(12):1160–2.View ArticlePubMedGoogle Scholar
- Yang Q, Modi P, Newcomb T, Queva C, Gandhi V. Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res. 2015;21(7):1537–42.View ArticlePubMedGoogle Scholar
- Iragavarapu C, Mustafa M, Akinleye A, Furqan M, Mittal V, Cang S, et al. Novel ALK inhibitors in clinical use and development. J Hematol Oncol. 2015;8(1):17.View ArticlePubMedPubMed CentralGoogle Scholar
- Parikh K, Cang S, Sekhri A, Liu D. Selective inhibitors of nuclear export (SINE)—a novel class of anti-cancer agents. J Hematol Oncol. 2014;7(1):78.View ArticlePubMedPubMed CentralGoogle Scholar
- Das A, Wei G, Parikh K, Liu D. Selective inhibitors of nuclear export (SINE) in hematological malignancies. Exp Hematol Oncol. 2015;4:7.View ArticlePubMedPubMed CentralGoogle Scholar
- Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8.View ArticlePubMedGoogle Scholar
- Zhao X, Rajasekaran N, Reusch U, Weichel M, Ellwanger K, Marschner J-P, et al. In vitro and in vivo characterization of CD19/CD3 Tandab AFM11 and CD19/CD16A Tandab AFM12 targeting NHL. Blood. 2015;126(23):2763.Google Scholar